GlassScriptPhysician profile
Tabitha D Luke
NPI 1407520463
$1,121.78
in general payments reported to CMS, 2019-2025
14 companies · $497 in 2025
The $497 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.87 · 2022: $35.49 · 2023: $173 · 2024: $386 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $236.70 | 2024 | Farxiga |
| Exact Sciences Corporation | $184.28 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $165.44 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Hologic Sales and Service, LLC | $149.17 | 2024 | Aptima |
| Merck Sharp & Dohme LLC | $111.20 | 2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $85.97 | 2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $46.10 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $30.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.29 | 2023 | Austedo |
| Novo Nordisk INC | $20.26 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $19.25 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.13 | 2025 | Rexulti |
| Vifor Pharma, INC. | $16.24 | 2022 | |
| Pfizer INC. | $14.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.